Nowadays the nanocarrier strategy, aimed to rebuild thetumor therapy approach in a winning way, is growingvery fast. This is in the direction to engendernanocarriers having synergistic action by the “biologicaldrugs” transported, the capability to recognize specifictargets and the molecular architecture that allows themto perform at the best their therapeutic functions.We are building engineered nanocarriers havingdifferent functions (control cell cycle, induce apoptosis,etc.) as well as the capability to recognize specifictargets (tumor cells, angiogenic and/or sproutingendothelial cells); moreover, they must have also theability to escape the host immunosystem, such that notto be toxic to healthy cells.At the present, poly(N-vinyl pyrrolidone) [PVP]nanogels with narrow-size distribution have beenproduced by applying an inverse microemulsionpolymerisation procedure, starting from vinylpyrrolidone (VP) and methyl-bis-acrylamide (MBA).Nanogels have been formed through a free-radicalchemical polymerisation occurring inside the watermicelles suspended into an oil phase by the recourse to asurfactant.The generated nanogels, marked by the inclusion “insitu” of FITC-Dextran or by direct copolymerisation withfluorescein O,O’-diacrylate, after purification wereevaluated for their capability to interact with plasmamembrane structures or to penetrate with time into thecultured cells by applying confocal microscopyanalysis. Moreover, they were tested for their ability toinduce apoptotic and/or necrotic processes to “in vitro”treated cells.
|Number of pages||1|
|Publication status||Published - 2009|